These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18614349)

  • 1. Angiogenesis as a target in neuroblastoma.
    Rössler J; Taylor M; Geoerger B; Farace F; Lagodny J; Peschka-Süss R; Niemeyer CM; Vassal G
    Eur J Cancer; 2008 Aug; 44(12):1645-56. PubMed ID: 18614349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-angiogenesis in neuroblastoma.
    Ribatti D
    Crit Rev Oncol Hematol; 2013 Jun; 86(3):212-21. PubMed ID: 23273512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Potential role of antiangiogenic treatment in neuroblastoma].
    Taylor M; Geoerger B; Lagodny J; Farace F; Vassal G; Rössler J
    Arch Pediatr; 2009 May; 16(5):457-67. PubMed ID: 19299115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis.
    Chlenski A; Liu S; Crawford SE; Volpert OV; DeVries GH; Evangelista A; Yang Q; Salwen HR; Farrer R; Bray J; Cohn SL
    Cancer Res; 2002 Dec; 62(24):7357-63. PubMed ID: 12499280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecularly guided therapy of neuroblastoma: a review of different approaches.
    Tonini GP; Pistoia V
    Curr Pharm Des; 2006; 12(18):2303-17. PubMed ID: 16787256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-mediated anti-angiogenic therapy for neuroblastoma.
    Streck CJ; Ng CY; Zhang Y; Zhou J; Nathwani AC; Davidoff AM
    Cancer Lett; 2005 Oct; 228(1-2):163-70. PubMed ID: 15927362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma.
    Ribatti D; Poliani PL; Longo V; Mangieri D; Nico B; Vacca A
    Histopathology; 2007 Apr; 50(5):636-41. PubMed ID: 17394500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in targeted anti-vasculature therapy: the neuroblastoma model.
    Pastorino F; Di Paolo D; Loi M; Becherini P; Caffa I; Zorzoli A; Marimpietri D; Carosio R; Perri P; Montaldo PG; Brignole C; Pagnan G; Ribatti D; Allen TM; Ponzoni M
    Curr Drug Targets; 2009 Oct; 10(10):1021-7. PubMed ID: 19663770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenretinide as an anti-angiogenic agent in neuroblastoma.
    Ribatti D; Raffaghello L; Marimpietri D; Cosimo E; Montaldo PG; Nico B; Vacca A; Ponzoni M
    Cancer Lett; 2003 Jul; 197(1-2):181-4. PubMed ID: 12880979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts.
    Segerström L; Fuchs D; Bäckman U; Holmquist K; Christofferson R; Azarbayjani F
    Pediatr Res; 2006 Nov; 60(5):576-81. PubMed ID: 16988184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
    Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
    Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic strategies in neuroblastoma.
    Ribatti D; Ponzoni M
    Cancer Treat Rev; 2005 Feb; 31(1):27-34. PubMed ID: 15707702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
    Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-angiogenic therapy: Prospects for treatment of ocular tumors.
    Rosenblatt MI; Azar DT
    Semin Ophthalmol; 2006; 21(3):151-60. PubMed ID: 16912013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden.
    Katzenstein HM; Rademaker AW; Senger C; Salwen HR; Nguyen NN; Thorner PS; Litsas L; Cohn SL
    Clin Cancer Res; 1999 Dec; 5(12):4273-8. PubMed ID: 10632370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Cross-talk' between Schwannian stroma and neuroblasts promotes neuroblastoma tumor differentiation and inhibits angiogenesis.
    Liu S; Tian Y; Chlenski A; Yang Q; Salwen HR; Cohn SL
    Cancer Lett; 2005 Oct; 228(1-2):125-31. PubMed ID: 15935552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-angiogenic therapies in cancer: achievements and open questions.
    Ruegg C; Mutter N
    Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis and anti-angiogenesis in neuroblastoma.
    Ribatti D; Vacca A; Nico B; De Falco G; Giuseppe Montaldo P; Ponzoni M
    Eur J Cancer; 2002 Apr; 38(6):750-7. PubMed ID: 11937307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects for therapeutic inhibition of neuroblastoma angiogenesis.
    Shusterman S; Maris JM
    Cancer Lett; 2005 Oct; 228(1-2):171-9. PubMed ID: 15927358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.
    Yang Q; Tian Y; Liu S; Zeine R; Chlenski A; Salwen HR; Henkin J; Cohn SL
    Cancer Res; 2007 Feb; 67(4):1716-24. PubMed ID: 17308113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.